

Resource Summary Report

Generated by [nidm-terms](#) on Sep 21, 2026

EU Clinical Trials Register

RRID:SCR_005956

Type: Tool

Proper Citation

EU Clinical Trials Register (RRID:SCR_005956)

Resource Information

URL: <https://www.clinicaltrialsregister.eu>

Proper Citation: EU Clinical Trials Register (RRID:SCR_005956)

Description: Database of European clinical trials containing information on interventional clinical trials on medicines. The information available dates from 1 May 2004 when national medicine regulatory authorities began populating the EudraCT database, the application that is used by national medicine regulatory authorities to enter clinical trial data. The EU Clinical Trials Register website launched on 22 March 2011 enables users to search for information which has been included in the EudraCT database. Users are able to: * view the description of a phase II-IV adult clinical trial where the investigator sites are in European Union member states and the European Economic Area; * view the description of any pediatric clinical trial with investigator sites in the European Union and any trials which form part of a pediatric investigation plan (PIP) including those where the investigator sites are outside the European Union. * download up to 20 results (per request) in a text file (.txt). The details in the clinical trial description include: * the design of the trial; * the sponsor; * the investigational medicine (trade name or active substance identification); * the therapeutic areas; * the status (authorized, ongoing, complete).

Synonyms: Clinicaltrialsregister.eu, European Union Clinical Trials Register, clinical trials register

Resource Type: data or information resource, database

Keywords: clinical trial, clinical, drug, pediatric, adult human, child, medicine, intervention, FASEB list

Availability: Public

Resource Name: EU Clinical Trials Register

Resource ID: SCR_005956

Alternate IDs: nlx_151313

License URLs: <https://www.clinicaltrialsregister.eu/disclaimer.html>

Record Creation Time: 20220129T080233+0000

Record Last Update: 20260919T195655+0000

Ratings and Alerts

No rating or validation information has been found for EU Clinical Trials Register.

No alerts have been found for EU Clinical Trials Register.

Data and Source Information

Source: [SciCrunch Registry](#)

Usage and Citation Metrics

We found 535 mentions in open access literature.

Listed below are recent publications. The full list is available at [nidm-terms](#) .

Foerster Y, et al. (2026) Sirolimus for Secondary Prevention of Cutaneous Squamous Cell Carcinoma in Kidney Transplant Recipients: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. International journal of dermatology, 65(5), 952.

Karaszewski B, et al. (2026) Reperfusion thrombolytic therapy for ischemic stroke in patients on non-vitamin K antagonist oral anticoagulants: study protocol of a phase II randomized clinical trial. Trials, 27(1).

Ying D, et al. (2026) Population-scale genomic medicine with the Hong Kong Genome Project. Nature medicine, 32(6), 2277.

Arroyo-Fernández R, et al. (2026) Effectiveness of Therapeutic Exercise in Reducing the Severity of Primary Dysmenorrhea and Associated Symptoms: A Systematic Review and Meta-Analysis. Journal of clinical medicine, 15(12).

Bourgeat P, et al. (2026) AI-enhanced Centiloid quantification of amyloid PET images. Alzheimer's & dementia : the journal of the Alzheimer's Association, 22(2), e71162.

Knuutila A, et al. (2026) The Effect of Pertussis Vaccination During Pregnancy on the Binding Epitopes and Avidity of Anti-Pertussis Toxin Immunoglobulin G Antibodies in Infants and Their Mothers. The Journal of infectious diseases, 233(4), e963.

Wegerif ECJ, et al. (2026) Haemorrhagic Safety Update of CLEAR-PATH: 30 Day and 12 Month Antiplatelet Therapy After Peripheral Angioplasty. EJVES vascular forum, 65, 32.

Rehberg S, et al. (2026) Pharmacokinetics of Landiolol and Its Metabolite M1 During Renal Replacement Therapy in Septic Shock Patients: A Sub-Study of the Landi-SEP Trial. *European journal of drug metabolism and pharmacokinetics*, 51(3), 305.

Agostini V, et al. (2026) Pediatric Investigation Plans for seizure and epilepsy treatments: An analysis since the implementation of the European Pediatric Regulation in 2006. *Epilepsia*, 67(3), 1267.

Sanduzzi-Zamparelli M, et al. (2026) Clinical Trial: Early Nivolumab Addition to Regorafenib in Patients With Hepatocellular Carcinoma in Second-Line (The GOING Trial). *Alimentary pharmacology & therapeutics*, 63(7), 955.

Merieme L, et al. (2026) Calcium enriched mixture versus mineral trioxide aggregate in vital pulp therapy in primary teeth: a systematic review. *Annals of medicine and surgery* (2012), 88(3), 2357.

Wang Y, et al. (2026) Bioinformatics profiling of NECTIN4 in lung cancer and comparative evaluation of NECTIN4-targeted ^{67}Ga -N188 and ^{18}F -FDG PET/CT. *Journal of translational medicine*, 24(1).

Main AM, et al. (2026) Changes in circulating small non-coding RNAs after castration in a cohort of prostate cancer patients. *Scientific reports*, 16(1), 7060.

Blanco FJ, et al. (2026) Clinical and molecular data to predict flares in DMARD optimization in rheumatoid arthritis: a randomized, controlled, open-label, non-inferiority trial. *Rheumatology (Oxford, England)*, 65(3).

St John M, et al. (2026) Interventions for childhood apraxia of speech. *The Cochrane database of systematic reviews*, 2(2), CD016149.

Laszig S, et al. (2026) CPX-351 in Down syndrome-associated myeloid leukemia: results and prognostic factors from the phase 3 ML-DS 2018 trial. *Blood*, 147(3), 229.

Tang B, et al. (2026) Efficacy and safety of manufactured Chinese herbal formula for cervical radiculopathy: a systematic review with meta-analysis and trial sequential analysis. *Frontiers in neuroscience*, 20, 1721569.

Chen C, et al. (2026) Evolution of Drug Development Trends in Multiple Sclerosis: Analysis of Mainland China and Global Landscapes From 2004 to 2024. *CNS neuroscience & therapeutics*, 32(4), e70870.

de Andrés-López J, et al. (2026) Small peptides derived from the autoinhibitory XY linker of phospholipase C- α isoforms inhibit enzyme activity and reduce inflammation. *Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie*, 198, 119272.

Bentvelzen MLM, et al. (2026) Disentangling patient, disease, and treatment effects: proteomic and metabolomic differences in early versus established psoriatic arthritis. *Rheumatology advances in practice*, 10(1), rkaf136.